Fibrobiologics Inc (FBLG)

$0.77 -0.03 (-3.72%)
Market Cap 4.17M
Revenue (ttm) 0.00
Net Income (ttm) -18.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 160,400
Avg Vol 253,108
Day's Range N/A - N/A
Shares Out 5.21M
Stochastic %K 0%
Beta 1.13
Analysts Sell
Price Target $8.00

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 671 5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
Niddi
Niddi Jun. 17 at 7:24 PM
$FBLG Infiltrated by manipulators. Bought more. Cheapies!
0 · Reply
FirstRebel
FirstRebel Jun. 16 at 11:42 PM
$FBLG out red 6200 and change. Good riddance
0 · Reply
Niddi
Niddi Jun. 16 at 4:39 PM
$FBLG It’s very obvious at level II that some immature short is trying to manipulate the price by fixing buy/sell price. I am adding. It’s just a matter of time before a significant news will be released and this will jump up.
1 · Reply
Niddi
Niddi Jun. 16 at 4:16 PM
$FBLG It’s being shorted.
0 · Reply
Niddi
Niddi Jun. 16 at 2:45 PM
$FBLG Good value to add.
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:28 PM
$FBLG 08:38 on Jun. 16 2026 CORRECTION: FibroBiologics Announces Data From CYPS317 Study For Psoriasis Was Announced On May 22, 2026 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:28 PM
$FBLG 08:35 on Jun. 16 2026 FibroBiologics Announces Data From CYPS317 Study For Psoriasis Demonstrates HDF Spheroids And Single-Cell HDF Preparations Lower Disease Severity; Signification Reductions In PASI Scores Seen #tradeideas
0 · Reply
FirstRebel
FirstRebel Jun. 15 at 5:18 PM
$FBLG no. By the time it comes around it be .60 and won't get back to a dollar until it reverse splits
1 · Reply
MisoHawny
MisoHawny Jun. 15 at 4:42 PM
$FBLG hmmmm
0 · Reply
Enoch120
Enoch120 Jun. 15 at 2:50 PM
$FBLG Is the fibroblast cell-based therapies for FBLG worth the wait?
1 · Reply
Latest News on FBLG
FibroBiologics doses first patients in CYWC628 clinical trial

2026-06-16T12:58:52.000Z - 3 days ago

FibroBiologics doses first patients in CYWC628 clinical trial

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers

Jun 16, 2026, 8:30 AM EDT - 3 days ago

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics doses first patients in CYWC628 trial

2026-06-03T12:30:49.000Z - 16 days ago

FibroBiologics doses first patients in CYWC628 trial

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

Jun 3, 2026, 7:00 AM EDT - 16 days ago

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics presents preclinical data from CYPS317 program

2026-05-22T12:45:44.000Z - 4 weeks ago

FibroBiologics presents preclinical data from CYPS317 program

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

May 22, 2026, 8:30 AM EDT - 4 weeks ago

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

May 18, 2026, 8:30 AM EDT - 4 weeks ago

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

FibroBiologics expands fibroblast-based platform to target Hantavirus

2026-05-11T14:42:59.000Z - 5 weeks ago

FibroBiologics expands fibroblast-based platform to target Hantavirus

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 11, 2026, 8:30 AM EDT - 5 weeks ago

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics CEO Issues Letter to Shareholders

May 5, 2026, 8:30 AM EDT - 6 weeks ago

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 6 weeks ago

FibroBiologics Proxy statement: Proxy filing

FibroBiologics Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 6 weeks ago

FibroBiologics Proxy statement: Proxy filing

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

2026-05-04T21:05:51.000Z - 6 weeks ago

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

May 4, 2026, 4:01 PM EDT - 6 weeks ago

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

2026-05-04T13:30:12.000Z - 6 weeks ago

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

May 4, 2026, 8:30 AM EDT - 6 weeks ago

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics downgraded to Hold from Buy at Maxim

2026-05-04T12:28:08.000Z - 6 weeks ago

FibroBiologics downgraded to Hold from Buy at Maxim

FibroBiologics reports Q1 net loss roughly ($5M)

2026-04-30T22:00:27.000Z - 7 weeks ago

FibroBiologics reports Q1 net loss roughly ($5M)

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Apr 30, 2026, 5:55 PM EDT - 7 weeks ago

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

Apr 30, 2026, 8:30 AM EDT - 7 weeks ago

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

FibroBiologics Quarterly report: Q1 2026

FibroBiologics Earnings release: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 7 weeks ago

FibroBiologics Earnings release: Q1 2026

FibroBiologics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

FibroBiologics Proxy statement: Proxy filing

FibroBiologics announces compliance with all Nasdaq listing requirements

2026-04-20T20:23:12.000Z - 2 months ago

FibroBiologics announces compliance with all Nasdaq listing requirements

FibroBiologics Compliant with All Nasdaq Listing Requirements

Apr 20, 2026, 4:01 PM EDT - 2 months ago

FibroBiologics Compliant with All Nasdaq Listing Requirements

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

2026-04-16T14:53:32.000Z - 2 months ago

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Apr 10, 2026, 8:30 AM EDT - 2 months ago

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

FibroBiologics Announces Closing of $3 Million Public Offering

Apr 2, 2026, 4:01 PM EDT - 2 months ago

FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics prices $3M public offering

2026-04-01T00:05:13.000Z - 2 months ago

FibroBiologics prices $3M public offering

FibroBiologics Announces Pricing of $3 Million Public Offering

Mar 31, 2026, 8:00 PM EDT - 2 months ago

FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics manufactures first batch of CYWC628 drug product for trials

2026-03-31T20:41:40.000Z - 2 months ago

FibroBiologics manufactures first batch of CYWC628 drug product for trials

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Mar 31, 2026, 4:15 PM EDT - 2 months ago

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Fibrobiologics Inc trading halted, news pending

2026-03-27T23:50:16.000Z - 2 months ago

Fibrobiologics Inc trading halted, news pending

FibroBiologics files to sell 1.14M shares of common stock, warrants

2026-03-27T21:25:14.000Z - 2 months ago

FibroBiologics files to sell 1.14M shares of common stock, warrants

FibroBiologics Registration statement: Registration filing

Mar 27, 2026, 8:00 AM EDT - 3 months ago

FibroBiologics Registration statement: Registration filing

FibroBiologics downgraded to Hold from Buy at D. Boral Capital

2026-03-26T11:21:11.000Z - 3 months ago

FibroBiologics downgraded to Hold from Buy at D. Boral Capital

FibroBiologics announces 1-for-20 reverse stock split

2026-03-25T20:50:15.000Z - 3 months ago

FibroBiologics announces 1-for-20 reverse stock split

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

Mar 25, 2026, 4:30 PM EDT - 3 months ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

FibroBiologics announces expansion of wound care platform

2026-03-12T12:48:33.000Z - 3 months ago

FibroBiologics announces expansion of wound care platform

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

Mar 12, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628

2026-03-05T13:48:24.000Z - 3 months ago

FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Mar 5, 2026, 8:30 AM EST - 3 months ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics announces issuance of U.S. patent covering fibroblast therapy

2026-03-02T13:48:25.000Z - 3 months ago

FibroBiologics announces issuance of U.S. patent covering fibroblast therapy

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Mar 2, 2026, 8:30 AM EST - 3 months ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb 26, 2026, 8:30 AM EST - 4 months ago

FibroBiologics to Present at the BIO Investment & Growth Summit

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 4:30 PM EST - 4 months ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

FibroBiologics Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 4 months ago

FibroBiologics Earnings release: Q4 2025

FibroBiologics Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 4 months ago

FibroBiologics Annual report: Q4 2025

FibroBiologics Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 4 months ago

FibroBiologics Annual report: Q4 2025

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 23, 2026, 8:30 AM EST - 4 months ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

FibroBiologics Transcript: EGM 2026

Feb 20, 2026, 12:00 PM EST - 4 months ago

FibroBiologics Transcript: EGM 2026

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 10, 2026, 8:30 AM EST - 4 months ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Feb 5, 2026, 8:30 AM EST - 4 months ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 20, 2026, 8:30 AM EST - 5 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 6, 2026, 8:30 AM EST - 5 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Jan 5, 2026, 8:30 AM EST - 5 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 31, 2025, 8:30 AM EST - 6 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

FibroBiologics Proxy statement: Proxy Filing

FibroBiologics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

FibroBiologics Proxy statement: Proxy Filing

FibroBiologics Registration statement: Registration Filing

Dec 23, 2025, 7:00 AM EST - 6 months ago

FibroBiologics Registration statement: Registration Filing

FibroBiologics Proxy statement: Proxy Filing

Dec 18, 2025, 7:00 AM EST - 6 months ago

FibroBiologics Proxy statement: Proxy Filing

FibroBiologics Proxy statement: Proxy Filing

Dec 18, 2025, 7:00 AM EST - 6 months ago

FibroBiologics Proxy statement: Proxy Filing

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:05 PM EST - 6 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 6 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Dec 10, 2025, 8:30 AM EST - 6 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 7 months ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 7 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 7 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 7 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 7 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 7 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 8 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Earnings release: Q3 2025

Oct 31, 2025, 4:00 PM EDT - 8 months ago

FibroBiologics Earnings release: Q3 2025

FibroBiologics Quarterly report: Q3 2025

Oct 31, 2025, 4:00 PM EDT - 8 months ago

FibroBiologics Quarterly report: Q3 2025

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 11 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Earnings release: Q2 2025

Jul 31, 2025, 4:00 PM EDT - 11 months ago

FibroBiologics Earnings release: Q2 2025

FibroBiologics Quarterly report: Q2 2025

Jul 31, 2025, 4:00 PM EDT - 11 months ago

FibroBiologics Quarterly report: Q2 2025

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 1 year ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 1 year ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Niddi
Niddi Jun. 17 at 7:24 PM
$FBLG Infiltrated by manipulators. Bought more. Cheapies!
0 · Reply
FirstRebel
FirstRebel Jun. 16 at 11:42 PM
$FBLG out red 6200 and change. Good riddance
0 · Reply
Niddi
Niddi Jun. 16 at 4:39 PM
$FBLG It’s very obvious at level II that some immature short is trying to manipulate the price by fixing buy/sell price. I am adding. It’s just a matter of time before a significant news will be released and this will jump up.
1 · Reply
Niddi
Niddi Jun. 16 at 4:16 PM
$FBLG It’s being shorted.
0 · Reply
Niddi
Niddi Jun. 16 at 2:45 PM
$FBLG Good value to add.
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:28 PM
$FBLG 08:38 on Jun. 16 2026 CORRECTION: FibroBiologics Announces Data From CYPS317 Study For Psoriasis Was Announced On May 22, 2026 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:28 PM
$FBLG 08:35 on Jun. 16 2026 FibroBiologics Announces Data From CYPS317 Study For Psoriasis Demonstrates HDF Spheroids And Single-Cell HDF Preparations Lower Disease Severity; Signification Reductions In PASI Scores Seen #tradeideas
0 · Reply
FirstRebel
FirstRebel Jun. 15 at 5:18 PM
$FBLG no. By the time it comes around it be .60 and won't get back to a dollar until it reverse splits
1 · Reply
MisoHawny
MisoHawny Jun. 15 at 4:42 PM
$FBLG hmmmm
0 · Reply
Enoch120
Enoch120 Jun. 15 at 2:50 PM
$FBLG Is the fibroblast cell-based therapies for FBLG worth the wait?
1 · Reply
FirstRebel
FirstRebel Jun. 12 at 7:16 PM
$FBLG terrible company to invest in. Terrible leadership.
0 · Reply
MisoHawny
MisoHawny Jun. 12 at 2:11 PM
$FBLG hmmm
0 · Reply
KardiTheViking
KardiTheViking Jun. 11 at 2:01 PM
$FBLG problem here is with the production batch for the trial ready in March, knowing the first patience dosed now makes it quite long from here 💆🏻‍♂️
0 · Reply
MisoHawny
MisoHawny Jun. 11 at 11:56 AM
$FBLG 89
0 · Reply
Niddi
Niddi Jun. 10 at 7:34 PM
$FBLG Being manipulated to shake off weak hands. Easily done with low volume.
0 · Reply
Niddi
Niddi Jun. 9 at 3:28 PM
$FBLG Someone is accumulating cheap shares.
1 · Reply
MisoHawny
MisoHawny Jun. 9 at 12:15 PM
$FBLG it’s possible that we reversed at 97.
0 · Reply
Niddi
Niddi Jun. 5 at 4:06 PM
$FBLG Naked shorting.
0 · Reply
Darksoul
Darksoul Jun. 5 at 1:07 AM
$FBLG unreal. Wtf news is needed for folks to see the good here. Oh wellz.
0 · Reply
Niddi
Niddi Jun. 5 at 12:53 AM
$FBLG Opportunity to add.
1 · Reply
MisoHawny
MisoHawny Jun. 4 at 11:53 PM
$FBLG it’s sitting exactly at 1 in after hours. Four times hitting that exact level. No, there’s no Algo at all. 
0 · Reply
Niddi
Niddi Jun. 4 at 6:29 PM
$FBLG Added/Adding. Cheap shares.
0 · Reply